View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2020updated 12 Jul 2022 11:35am

Ampio Pharmaceuticals concludes enrolment in Covid-19 trial

US-based biopharmaceutical firm Ampio Pharmaceuticals has completed enrolment for its Phase I clinical trial of Ampion intravenous treatment for Covid-19 patients who need supplemental oxygen.

US-based biopharmaceutical firm Ampio Pharmaceuticals has completed enrolment for its Phase I clinical trial of Ampion intravenous treatment for Covid-19 patients who need supplemental oxygen.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The safety monitoring committee (SMC) and the principal investigator are expected to complete their review this week. Based on the review findings, the company will report the final data from the five-day treatment regimen.

Ampion is the company’s lead product candidate being developed to treat prevalent inflammatory conditions with limited therapy options.

The company started patient enrolment and dosing in the Phase I Covid-19 trial in July. The primary endpoint is the safety and tolerability of IV Ampion treatment in adult patients.

Ampion is expected to hinder the inflammatory cascade caused by Covid-19 infection and improve the clinical course and outcome of patients.

Trial principal investigator Dr Michael Roshon said: “Our understanding of Covid-19 continues to evolve and we are pleased to partner with Ampio in this trial to assess Ampion’s potential as a treatment in the fight against Covid-19.

“It is clear that modulation of the immune response to Covid-19 is one of the most promising therapeutic targets. We are very interested in investigating Ampion’s effect on inflammation in this setting.”

The drug candidate is also being evaluated in a Phase III study of an intra-articular formulation for the treatment of severe osteoarthritis of the knee (OAK).

This Phase III study was paused in April 2020 over logistical issues related to the Covid-19 pandemic.

In compliance with the US Food and Drug Administration (FDA) guidance, the company remains blinded to the data captured before pausing the trial.

The company anticipates enough objective information to support the submission of its proposal to the FDA. The aim is to complete and send the proposal to the FDA in the fourth quarter of this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena